Jim Kras; President, Chief Executive Officer, Director; Edible Garden AG Inc Kostas Dafoulas; Interim Chief Financial Officer; Edible Garden AG Inc Greetings and welcome to the Edible Garden AG ...

Edible Garden AG Incorporated ("Edible Garden” or the "Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment ...

Recent advancements in cancer therapy focus on targeting critical mutations and regulatory pathways, particularly KRAS mutations and cyclin-dependent kinases (CDKs), which drive cancer progression.

The study, featured on the cover of the Journal of Thoracic Oncology, reveals a potential game-changer for patients battling tumors with the KRAS G12C mutation-a driver in about 14% of non-small ...

ALTA3263 is designed for complete KRAS target coverage, which will be required to achieve breakthrough efficacy and safety for patients with KRAS-driven cancers SAN DIEGO--(BUSINESS WIRE)--Alterome ...

NEW YORK – Alterome Therapeutics said on Monday it has started treating patients with KRAS-mutant advanced solid tumors with its KRAS inhibitor ALTA3263 in a Phase I trial. The researchers will enroll ...